-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
2023-03-13
Like! Lü Xiaolong, a post-00s employee at Guangxiang Pharmaceutical, part of Shijiazhuang Fourth Pharmaceutical Group, has successfully donated hematopoietic stem cells.
On the morning of February 27, in the hematopoietic stem cell collection room of the Third Hospital of Hebei Medical University, after more than five hours of collection, a young man born in the 2000s successfully donated 395 milliliters of hematopoietic stem cell suspension. These “seeds of life,” destined for distant recipients, carry with them profound love and the hope of renewed vitality. This young man from the 2000s is Lü Xiaolong, who works in the warehousing service department of Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shijiazhuang Sihua Pharmaceutical Group. He is also the second employee from this group to successfully donate hematopoietic stem cells.
2023-02-10
Guangxiang Pharmaceutical Group was awarded the title of “Occupational Health Enterprise” for 2022 by Hebei Province.
Recently, six departments—the Hebei Provincial Health Commission, the Provincial Department of Industry and Information Technology, the Provincial Department of Ecology and Environment, the Provincial Federation of Trade Unions, the Communist Youth League Hebei Provincial Committee, and the Provincial Women’s Federation—jointly released the list of “Occupational Health Enterprises” for Hebei Province in 2022. Hebei Guangxiang Pharmaceutical Co., Ltd., part of our group, was successfully included on the list and awarded the title of “Occupational Health Enterprise” by the province.
2023-01-07
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has been recognized as a provincial demonstration enterprise for technological innovation.
On January 6, the Hebei Provincial Department of Industry and Information Technology released the list of provincial-level demonstration enterprises for technological innovation for 2022. Among them, 36 companies—including Hebei Guangxiang Pharmaceutical Co., Ltd.—were recognized by the Provincial Department of Industry and Information Technology as provincial-level demonstration enterprises for technological innovation in 2022.
Recently, the Hebei Provincial Department of Industry and Information Technology released the fourth list of provincial manufacturing single-champion enterprises and single-champion products. Both Metronidazole produced by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Siyao Group, and Hydroxyethyl Starch produced by Hebei Guolong Pharmaceutical Co., Ltd. have been recognized as Hebei Province’s manufacturing single-champion products.
31
2022/12
Currently, Hebei Guangxiang Pharmaceutical Co., Ltd. has embarked on the journey to become a nationally recognized “Little Giant” enterprise specializing in niche, sophisticated, and innovative products. The company has identified untapped market segments and is poised to deepen its expertise in specialty pharmaceutical ingredients. Leveraging a series of supportive policies at the national, provincial, and municipal levels aimed at fostering the development of the biopharmaceutical industry, Guangxiang is steadily increasing its R&D investment and continuously driving its business forward to reach new heights and achieve breakthroughs.
13
2022/11
Recently, the active pharmaceutical ingredient—aggrastat—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has been approved by the National Medical Products Administration for registration as an API intended for use in marketed formulations.
07
2022/09
Recently, the Department of Industry and Information Technology of Hebei Province announced the list of key cultivation projects for innovative development of the provincial industrial internet in 2022. The high-end intelligent manufacturing upgrade project for active pharmaceutical ingredients (APIs) of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Siyao Group, was included on the list of key cultivation projects.
29
2022/07
On June 23, the active pharmaceutical ingredient—rosuvastatin calcium—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Four Pharmaceutical Group, was approved by the National Medical Products Administration and has been registered as an active pharmaceutical ingredient for use in marketed formulations.
23
2022/06
Recently, three active pharmaceutical ingredients—pentoxifylline, levonidazole, and ornidazole—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, have been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
27
2022/05
Against the backdrop of implementing the country’s new development philosophy and accelerating the transition from a major pharmaceutical producer to a powerful pharmaceutical nation, China’s leading pharmaceutical company, Shijiazhuang Fourth Pharmaceutical Group (referred to as “Shijiazhuang Fourth Pharma”), is vigorously pursuing a “API + Finished Dosage Form” development strategy. Through strategic capital partnerships, acquisitions, and restructuring, the company is actively expanding its upstream and downstream industrial chains, enhancing its competitiveness in both domestic and international markets, and injecting fresh momentum into the accelerated development of its API business segment. A series of significant initiatives are propelling Shijiazhuang Fourth Pharmaceutical Group toward its goal of becoming a leading API manufacturer.
23
2022/05
Shijiazhuang Fourth Pharmaceutical Group has once again received good news from its research and development efforts. Recently, the active pharmaceutical ingredient—lacosamide—developed and submitted by the group’s Hebei Guangxiang Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
17
2022/05
Recently, the active pharmaceutical ingredient—pitavastatin calcium—developed and submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Four Pharmaceutical Group, has been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
14
2022/05
Our flagship product, caffeine, and other related products have all seen robust growth in both production and sales. Seven new specialty pharmaceutical ingredients—including hexamethylenetetramine and ornidazole—are set to receive approval and launch soon. In the first quarter, our core business revenue achieved triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has delivered an impressive “combination punch,” ushering in a strong start to its innovative development.
20
2022/04
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license